<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Women with prior <z:hpo ids='HP_0009800'>gestational diabetes</z:hpo> mellitus (pGDM) are at increased risk of developing type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and associated vasculopathy </plain></SENT>
<SENT sid="1" pm="."><plain>Because increased fat mass and inflammatory processes are angiopathic risk factors, the relationship between insulin sensitivity, parameters of subclinical <z:mp ids='MP_0001845'>inflammation</z:mp>, and plasma concentrations of adipocytokines was investigated in pGDM both at 3 months and 12 months after delivery </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: Insulin sensitivity (through a frequently sampled intravenous <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test) and plasma concentrations of ultrasensitive C-reactive protein (CRP), adiponectin, plasminogen activator inhibitor (PAI)-1, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha, leptin, and interleukin-6 were measured in 89 pGDM (BMI 26.9 +/- 0.5 kg/m(2), age 32 +/- 0.5 years) and in 19 women with <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance during pregnancy (NGT) (23.7 +/- 0.9 kg/m(2), 31 +/- 1.3 years) </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: pGDM showed lower (P &lt; 0.0001) plasma adiponectin (6.7 +/- 0.2 microg/ml) than NGT (9.8 +/- 0.6 microg/ml) and a decreased (P &lt; 0.003) insulin sensitivity index (S(i)) and disposition index (P &lt; 0.03), but increased plasma leptin (P &lt; 0.003), PAI-1 (P &lt; 0.002), and CRP (P &lt; 0.03) </plain></SENT>
<SENT sid="4" pm="."><plain>After adjustment for body fat mass, plasma adiponectin remained lower in pGDM (P &lt; 0.004) and correlated positively with S(i) (P &lt; 0.003) and <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> (P &lt; 0.0001) but negatively with plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (2-h oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test [OGTT]) (P &lt; 0.0001), leptin (P &lt; 0.01), CRP (P &lt; 0.007), and PAI-1 (P &lt; 0.0001) </plain></SENT>
<SENT sid="5" pm="."><plain>On regression analysis, only <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi>, postload (2-h OGTT) plasma <z:chebi fb="105" ids="17234">glucose</z:chebi>, and S(i) remained significant predictors of plasma adiponectin, explaining 42% of its variability </plain></SENT>
<SENT sid="6" pm="."><plain>Of note, adiponectin further decreased (P &lt; 0.05) only in insulin-resistant pGDM despite unchanged body fat content and distribution after a 1-year follow-up </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Lower plasma adiponectin concentrations characterize women with previous <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GDM</z:e> independently of the prevailing insulin sensitivity or the degree of <z:hpo ids='HP_0001513'>obesity</z:hpo> and are associated with subclinical <z:mp ids='MP_0001845'>inflammation</z:mp> and atherogenic parameters </plain></SENT>
</text></document>